4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0001193125-26-037570
Options or other derivatives
- Chief Scientific Officer acquired 103,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Bredt David Chief Scientific Officer | 2026-02-02 | Grant or award · Stock Option (Right to Buy) | +103,000 | 103,000 | D: show line 1 in the form |
Loading xslF345X05/ownership.xml…